{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/scarlet-fever/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"5b31f083-75b7-5ae3-9029-87df9bc061cf","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 48ddc0d6-03a4-4a8b-a6c4-63f56d1475d9 --><h2>How common is it?</h2><!-- end field 48ddc0d6-03a4-4a8b-a6c4-63f56d1475d9 -->","summary":"","htmlStringContent":"<!-- begin item ae0a6e49-2d2c-47ab-bafc-0cc5f9b991e7 --><!-- begin field dad64b3a-caf3-4cb2-a062-66a3f3c13564 --><ul><li><strong>Scarlet fever can occur at any age but is most common in children between 2–8 years of age (median age 4 years) </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2017</a>]<strong>.</strong><ul><li>The Public Health England (PHE) seasonal activity report for 2018/19 found an age distribution of 89% of cases in children under 10 years of age, and there was an equal split between males and females overall [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2020</a>]. </li><li>Incidence is seasonal, and in the UK most cases occur in the winter and spring months between December and May, peaking in March or April [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2017</a>].</li></ul></li><li><strong>Although scarlet fever is much less common than it used to be, there has been an upsurge in notified cases since 2013/14 </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2020</a>]<strong>.</strong><ul><li>PHE data for the first 2019/20 season show that increased levels of scarlet fever infection are continuing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2020</a>].<ul><li>A total of 7789 notifications of scarlet fever were received in the first 2019/20 season in England compared with an average of 5859 for the same period in the previous 5 years. This is the seventh consecutive season of recorded elevated scarlet fever activity in England.</li><li>Rates of infection were highest in 1–4 year olds (650 per 100,000 population) and lower in the adult population aged 45–64 years (7 per 100,000).</li></ul></li><li>A population-based surveillance study of PHE data found rates of scarlet fever infection increased by a factor of three between 2013 and 2014 from 8.2 to 27.2 per 100,000 population, and further increases were observed in 2015 (30.6 per 100,000) and in 2016 (33.2 per 100,000) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Lamagni, 2018</a>].</li></ul></li><li><strong>There has also been an increase in reported cases of invasive Group A Streptococcus (iGAS) infection </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">PHE, 2020</a>]<strong>.</strong><ul><li>PHE 2018/19 data reported 1052 notifications of iGAS disease in England, higher than the average for the previous 5 years. The median age of people with iGAS infection was 54 years, and rates of iGAS infection were highest in the 75 years and over age-group at 6 per 100,000 population.</li></ul></li></ul><!-- end field dad64b3a-caf3-4cb2-a062-66a3f3c13564 --><!-- end item ae0a6e49-2d2c-47ab-bafc-0cc5f9b991e7 -->","topic":{"id":"7c05f7c5-902d-5982-8cc9-5f1d301d214d","topicId":"f534013d-38dd-4f96-bc65-37091262952c","topicName":"Scarlet fever","slug":"scarlet-fever","lastRevised":"Last revised in March 2020","chapters":[{"id":"d3f6c278-a759-50f3-9a96-734913f439ab","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ffff4a88-7ddf-55dc-a37b-1625f3f58e2b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"89be33c0-acbe-51fd-901b-d7cf571435a4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61377ddb-df7a-50fb-9dd7-224014332a4e","slug":"changes","fullItemName":"Changes"},{"id":"b5e95aca-9003-52f8-b6e7-0c192c5ba757","slug":"update","fullItemName":"Update"}]},{"id":"90d2085f-63f5-57a1-b21e-21d4c580229a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cc3aa630-ef6b-5504-9439-6a4757e7fe43","slug":"goals","fullItemName":"Goals"},{"id":"ebf64432-58f2-513f-a393-ec4e8438f355","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b3da9abe-7cc8-5c97-970d-39b1416de8cb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8b3309e1-1d9f-520e-b310-592706c0951d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0603af50-edd7-5e78-a394-1fd6a1a1af21","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00da52ed-356a-563d-aa3c-dc4e3ee27155","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7072120a-72ec-5945-b4f0-e4386374e1ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f61354f7-80ff-5483-89fc-51be1d57b5d3","slug":"definition","fullItemName":"Definition"},{"id":"4dc22989-c1d3-5880-a381-78cabd38ca4d","slug":"transmission","fullItemName":"Transmission"},{"id":"c4e4e4ff-9b93-5d55-8ae0-5e0b1a518ef3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"5b31f083-75b7-5ae3-9029-87df9bc061cf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"94ffb885-96f6-595f-b1ad-fb146a27db30","slug":"complications","fullItemName":"Complications"},{"id":"f3bf38a0-7946-504a-b22c-654728a0366a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ffb84f0d-77eb-5011-a50d-14d9143e4bd4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8484304f-9507-5401-8c08-2c93126a8b3f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"601ddd63-7670-5740-a0f6-fe317e0d7770","slug":"investigations","fullItemName":"Investigations"},{"id":"a1df37ba-9251-52d5-8376-b19803e39cc3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5329e2f2-3618-5113-8fc1-5228ff864869","fullItemName":"Management","slug":"management","subChapters":[{"id":"963d805b-33a2-5e78-9195-323379519c7e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db4a097c-9d97-5e1e-8718-e082e8e25f5e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4a26593a-c9e4-5523-a6d2-5feb274dcf79","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"},{"id":"2a494a84-0688-5337-8f03-a2ab33a654fb","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"ce256942-e7de-5014-bdf7-f34be5755538","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"7e3b4438-f437-5199-8ee5-f3c9d210b732","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f2446794-c34e-574f-8de3-c5ecbe3c4f35","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1a90ff7f-b2b6-5959-86a0-3cea6609706f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d14df6f-1299-58da-b620-c970e5b90b91","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"db42b54d-b095-52b7-9cb1-37d73c57fdb7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"551dac2a-e65d-57c4-b16c-279891510a2b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5d76e530-4218-5600-a9ed-896a3245aefb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"03221ed8-00f7-5819-b90c-cc69c4a1fdb8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7072120a-72ec-5945-b4f0-e4386374e1ad","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}